Raised Series A1: $1.5M, seeking to close remaining $3.9M Series A2
Pre-clinical studies completed with over $5M in non-dilutive funding. IND ready!
Patent issued in 2015, WW exclusive license from Stanford University.
Experienced senior management team, scientific advisors, and Board of Directors with deep pharmaceutical industry expertise in place.
Phase 1 clinical sponsor selected: Head of Gynecologic Oncology at Stanford Women’s Cancer.
Clinical team in place.
Manufacturing in place.
Pre-IND briefing book filed Dec 2016.
Copyright © ConcentRx. All rights reserved.